Show simple item record

dc.contributor.authorModiri, A.
dc.contributor.authorSawant, A.
dc.contributor.authorBentzen, S.M.en_US
dc.date.accessioned2020-04-14T18:36:18Z
dc.date.available2020-04-14T18:36:18Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082499808&doi=10.1080%2f0284186X.2020.1733654&partnerID=40&md5=91384aaf2f720c57765ef2e77259b881
dc.identifier.urihttp://hdl.handle.net/10713/12573
dc.description.abstractPurpose: In current radiotherapy (RT) planning and delivery, population-based dose-volume constraints are used to limit the risk of toxicity from incidental irradiation of organs at risks (OARs). However, weighing tradeoffs between target coverage and doses to OARs (or prioritizing different OARs) in a quantitative way for each patient is challenging. We introduce a novel RT planning approach for patients with mediastinal Hodgkin lymphoma (HL) that aims to maximize overall outcome for each patient by optimizing on tumor control and mortality from late effects simultaneously. Material and Methods: We retrospectively analyzed 34 HL patients treated with conformal RT (3DCRT). We used published data to model recurrence and radiation-induced mortality from coronary heart disease and secondary lung and breast cancers. Patient-specific doses to the heart, lung, breast, and target were incorporated in the models as well as age, sex, and cardiac risk factors (CRFs). A preliminary plan of candidate beams was created for each patient in a commercial treatment planning system. From these candidate beams, outcome-optimized (O-OPT) plans for each patient were created with an in-house optimization code that minimized the individual risk of recurrence and mortality from late effects. O-OPT plans were compared to VMAT plans and clinical 3DCRT plans. Results: O-OPT plans generally had the lowest risk, followed by the clinical 3DCRT plans, then the VMAT plans with the highest risk with median (maximum) total risk values of 4.9 (11.1), 5.1 (17.7), and 7.6 (20.3)%, respectively (no CRFs). Compared to clinical 3DCRT plans, O-OPT planning reduced the total risk by at least 1% for 9/34 cases assuming no CRFs and 11/34 cases assuming presence of CRFs. Conclusions: We developed an individualized, outcome-optimized planning technique for HL. Some of the resulting plans were substantially different from clinical plans. The results varied depending on how risk models were defined or prioritized. Copyright 2020 The Author(s).en_US
dc.description.urihttps://doi.org/10.1080/0284186X.2020.1733654en_US
dc.language.isoen_USen_US
dc.publisherTaylor and Francis Ltden_US
dc.relation.ispartofActa Oncologica
dc.subject.meshHodgkin Disease--radiotherapyen_US
dc.subject.meshOrgans at Risken_US
dc.subject.meshRadiotherapy--methodsen_US
dc.titleBiological optimization for mediastinal lymphoma radiotherapy – a preliminary studyen_US
dc.typeArticleen_US
dc.identifier.doi10.1080/0284186X.2020.1733654
dc.identifier.pmid32216586


This item appears in the following Collection(s)

Show simple item record